Podrobný průvodce již brzy
Pracujeme na komplexním vzdělávacím průvodci pro GLP-1 Muscle Loss Risk Score. Brzy se vraťte pro podrobné vysvětlení, vzorce, příklady z praxe a odborné tipy.
The GLP-1 Muscle Loss Risk Calculator estimates the proportion of weight lost from lean mass versus fat mass during GLP-1 receptor agonist therapy and identifies modifiable risk factors that can shift the body composition outcome. In clinical trials, typically 25 to 40 percent of total weight lost on semaglutide or tirzepatide is lean mass (primarily skeletal muscle), a phenomenon that has generated significant clinical concern as these medications are used in increasingly large patient populations. Lean mass loss during weight loss is not unique to GLP-1 medications; it is a universal biological response to caloric deficit. The body, when deprived of energy, breaks down both fat and muscle tissue to meet its metabolic needs. However, the magnitude of weight loss achieved with modern GLP-1 drugs (15 to 22 percent of body weight) means that even a typical lean mass fraction of 25 to 30 percent can translate to a substantial absolute muscle loss of 8 to 15 pounds in a patient who loses 40 to 60 pounds total. This matters because muscle is metabolically active tissue that supports metabolic rate, physical function, bone health, and insulin sensitivity. The risk factors for excessive lean mass loss are well-characterized and largely modifiable. Inadequate protein intake (below 1.0 g/kg/day), absence of resistance training, age over 65, rapid rate of weight loss (more than 1 percent of body weight per week), and very low calorie intake (below 1,200 kcal/day) all increase the proportion of lean mass lost. Conversely, adequate protein (1.2 to 1.6 g/kg/day) combined with resistance training 2 to 3 times per week can reduce the lean mass fraction of weight loss to under 20 percent, dramatically improving body composition outcomes. This calculator is used by obesity medicine physicians to identify high-risk patients before initiating GLP-1 therapy, by exercise physiologists to justify resistance training prescriptions, by registered dietitians to emphasize protein adequacy, and by patients who want to understand and optimize their body composition trajectory during pharmacological weight loss.
Muscle Loss Risk Score = (Rate of Loss Factor x 0.30) + (Protein Deficit Factor x 0.25) + (Age Factor x 0.20) + (Exercise Factor x 0.25), where each factor is scored 0-100. Rate of Loss Factor = 100 if losing > 1.5% BW/week, 50 if 0.5-1.5%, 20 if < 0.5%. Protein Deficit Factor = 100 if < 0.8 g/kg, 50 if 0.8-1.2 g/kg, 20 if > 1.2 g/kg. Age Factor = 80 if > 65, 50 if 50-65, 20 if < 50. Exercise Factor = 100 if no resistance training, 50 if 1x/week, 20 if 2+x/week. Estimated Lean Mass % of Weight Lost = 15% + (Risk Score x 0.30). For a worked example: 55-year-old losing 1% BW/week (Rate = 50), eating 1.0 g/kg protein (Protein = 50), age factor 50, no resistance training (Exercise = 100). Score = (50 x 0.30) + (50 x 0.25) + (50 x 0.20) + (100 x 0.25) = 15 + 12.5 + 10 + 25 = 62.5. Estimated lean mass loss = 15 + (62.5 x 0.30) = 33.8% of total weight lost.
- 1Enter your current rate of weight loss, calculated as the average weekly weight change over the past 4 weeks divided by your current body weight and expressed as a percentage. A rate above 1 percent of body weight per week is considered rapid and increases the risk of lean mass loss because the body cannot mobilize fat stores fast enough to meet the entire energy deficit, forcing increased reliance on muscle protein breakdown. GLP-1 medications can produce rates of 1.5 to 2 percent per week during early months, particularly at higher doses.
- 2Enter your average daily protein intake in grams. If you do not track protein precisely, the calculator provides a food-based estimation tool where you select your typical protein-containing foods and servings. Protein is the single most impactful modifiable factor: patients consuming less than 0.8 g/kg per day experience nearly double the lean mass loss percentage compared to those consuming 1.2 g/kg or more. The calculator scores protein adequacy against the recommended 1.2 to 1.6 g/kg target.
- 3Enter your age. Adults over 65 face a significantly higher risk of clinically meaningful lean mass loss because they start with lower baseline muscle mass, have reduced anabolic response to protein (anabolic resistance), and are closer to the sarcopenia threshold where functional impairment begins. A 70-year-old who loses 5 pounds of lean mass may cross from normal muscle mass into sarcopenic territory, while a 35-year-old losing the same amount remains well above the threshold.
- 4Indicate your resistance training frequency: none, once per week, twice per week, or three or more times per week. Resistance training is the second most impactful modifiable factor after protein intake. It directly stimulates muscle protein synthesis, signals the body to preserve lean tissue during caloric deficit, and improves the fat-to-lean ratio of weight lost by 15 to 20 percentage points in multiple studies. Even modest resistance training (2 sessions per week of 30 minutes each) produces significant lean mass preservation.
- 5Enter your current total daily caloric intake if known. Very low calorie diets (below 1,200 kcal for women, 1,500 kcal for men) amplify lean mass loss risk independently of protein percentage, because the absolute energy deficit exceeds the rate at which fat oxidation can supply energy, forcing the body to catabolize more muscle protein. GLP-1 patients who report eating very little due to severe appetite suppression are at particular risk.
- 6Optionally enter body composition data if available. DEXA scan, bioelectrical impedance (BIA), or skinfold measurements provide a baseline lean mass estimate that the calculator uses to project the absolute pounds of lean mass at risk. While not required, body composition data transforms the output from a percentage-based risk estimate to an absolute lean mass loss projection in pounds or kilograms.
- 7Review the comprehensive risk assessment showing your overall risk score (low, moderate, or high), the estimated percentage of weight loss from lean mass, a breakdown of which risk factors are contributing most, and specific actionable recommendations to reduce your risk. For patients at high risk, the calculator generates a prioritized action plan: first increase protein to 1.4 g/kg, second add resistance training twice weekly, and third consider slowing the rate of weight loss by reducing the GLP-1 dose or adding calories.
This patient has multiple compounding risk factors: older age, rapid weight loss, severely inadequate protein, no resistance training, and very low caloric intake. The projected 40 percent lean mass loss means that nearly half of their weight loss is muscle, which could push them into clinical sarcopenia. Immediate intervention is critical.
This patient has optimized all modifiable risk factors: adequate protein, regular resistance training, moderate rate of loss, and sufficient calorie intake. Their lean mass loss percentage is near the physiological minimum for any weight loss intervention, comparable to outcomes seen in well-managed bariatric surgery patients.
This patient has good protein intake and moderate weight loss rate but the absence of resistance training is the primary risk factor. The calculator shows that adding just 2 resistance sessions per week would reduce the lean mass loss estimate from 31 to 23 percent, saving approximately 3 to 4 additional pounds of muscle over the course of treatment.
Obesity medicine clinics use the muscle loss risk calculator during the pre-treatment assessment to identify patients who need proactive body composition interventions before starting GLP-1 therapy. High-risk patients (older adults, those with low baseline muscle mass, those unable to exercise) may be referred to physical therapy or exercise physiology before or concurrently with medication initiation to establish a resistance training routine that will protect lean mass from the start.
Clinical researchers use lean mass loss risk models to design trials that evaluate interventions for preserving body composition during GLP-1 therapy. Several active clinical trials are studying the combination of GLP-1 medications with resistance training programs, high-protein diets, creatine supplementation, and even testosterone replacement to determine which combinations most effectively reduce the lean mass fraction of weight loss. The risk calculator helps researchers identify which patient subgroups to target in these trials.
Insurance companies and value-based care organizations are beginning to incorporate body composition outcomes into their quality metrics for obesity treatment programs. A program that achieves 15 percent total weight loss but with 35 percent lean mass loss may be considered lower quality than one achieving 12 percent weight loss with only 20 percent lean mass loss. The risk calculator helps programs predict and document their body composition outcomes for quality reporting.
Patients use the calculator as a motivational tool to understand why resistance training and protein intake are non-negotiable components of GLP-1 therapy, not optional add-ons. Seeing that specific, achievable changes (adding 2 gym sessions per week, increasing protein by 30 grams per day) can reduce their projected lean mass loss by 10 to 15 percentage points helps translate abstract nutritional advice into concrete, measurable action items.
Patients with pre-existing sarcopenia or low muscle mass (appendicular lean
Patients with pre-existing sarcopenia or low muscle mass (appendicular lean mass index below 7.0 kg/m2 for men or 5.5 kg/m2 for women) are at the highest risk of clinically significant functional impairment from GLP-1-related lean mass loss. For these patients, initiating a supervised resistance training program for 4 to 8 weeks before starting GLP-1 medication is recommended to build a buffer of lean mass. If this is not feasible, starting at the lowest dose and using the slowest titration pace reduces the rate of weight loss and lean mass depletion. Body composition monitoring by DEXA scan every 6 months is advisable.
Cancer survivors on GLP-1 therapy face elevated lean mass loss risk because
Cancer survivors on GLP-1 therapy face elevated lean mass loss risk because prior chemotherapy and radiation often cause cancer-related sarcopenia and anabolic resistance. Additionally, some patients may have dietary restrictions that limit protein intake. The calculator applies an additional risk multiplier for cancer survivorship and recommends oncology-informed exercise programming that accounts for treatment-related fatigue, neuropathy, or surgical limitations.
| Weight Loss Method | Mean %BWL | Lean Mass % of Loss | Key Study |
|---|---|---|---|
| GLP-1 alone (no RT) | 15-21% | 30-40% | STEP 1 DEXA substudy |
| GLP-1 + protein optimization | 14-20% | 25-30% | Observational data |
| GLP-1 + protein + resistance training | 13-18% | 15-22% | Emerging trial data |
| Diet-only (no medication) | 5-10% | 25-35% | Multiple meta-analyses |
| Bariatric surgery (RYGB) | 25-35% | 20-30% | Longitudinal surgical data |
| Very low calorie diet (<800 kcal) | 10-15% | 35-45% | VLCD studies |
How much muscle will I lose on GLP-1 medication?
Without specific interventions, clinical data shows that approximately 25 to 40 percent of weight lost on GLP-1 medications is lean mass. For a patient who loses 50 pounds, this means 12 to 20 pounds of lean mass. However, with adequate protein intake (1.2 to 1.6 g/kg/day) and regular resistance training (2 to 3 times per week), this can be reduced to 15 to 20 percent, meaning only 7 to 10 pounds of lean mass lost out of 50 pounds total. The interventions are highly effective and should be considered essential components of GLP-1 therapy.
Is muscle loss on GLP-1 medications worse than with other weight loss methods?
The lean mass fraction of weight loss on GLP-1 medications (25 to 40 percent) is comparable to other non-surgical weight loss methods and actually comparable to bariatric surgery (20 to 35 percent lean mass loss). The concern with GLP-1 medications is not that the percentage is uniquely high, but that the total amount of weight lost is much greater than with older methods, so the absolute lean mass loss in pounds is larger. A patient losing 50 pounds on semaglutide loses more total lean mass than a patient losing 20 pounds on a conventional diet, even if the lean mass percentage is similar.
Can I rebuild muscle after losing it on GLP-1 medication?
Yes, muscle can be rebuilt through resistance training and adequate protein intake, but it is a slow process. Building 1 to 2 pounds of muscle per month is considered a good rate even under optimal conditions (progressive resistance training, caloric surplus or maintenance, 1.6 g/kg protein). This means rebuilding 10 to 15 pounds of lost lean mass could take 6 to 12 months of dedicated strength training. It is far more efficient to preserve lean mass during weight loss than to try to rebuild it afterward, which is why prevention through concurrent resistance training is strongly emphasized.
What type of resistance training is best for preserving muscle during GLP-1 therapy?
The most effective resistance training for lean mass preservation during weight loss focuses on compound movements (squats, deadlifts, presses, rows) performed with moderate to heavy loads (60 to 80 percent of one-rep maximum) for 8 to 12 repetitions per set, 2 to 4 sets per exercise, targeting all major muscle groups at least twice per week. Progressive overload (gradually increasing weight or repetitions over time) is essential. Machine-based exercises are acceptable if free weights are not accessible. Even bodyweight exercises (push-ups, squats, lunges) provide benefit if performed near muscular fatigue. The key is consistency: training twice weekly is the minimum effective dose.
Does creatine supplementation help preserve muscle during GLP-1 therapy?
Creatine monohydrate (3 to 5 grams per day) is the most well-studied supplement for supporting muscle mass and strength, with strong evidence in both young and older adults. While specific studies in GLP-1 patients are limited, the physiological rationale is sound: creatine enhances the capacity for high-intensity resistance training (by replenishing phosphocreatine stores) and may have direct effects on muscle protein synthesis. It is inexpensive ($15 to $20 per month), well-tolerated, and has an excellent safety profile. Many obesity medicine specialists now recommend creatine alongside protein supplementation for GLP-1 patients doing resistance training.
Pro Tip
Invest in a simple body composition measurement early in your GLP-1 therapy journey, even an inexpensive bioelectrical impedance scale ($30 to $50), so you can track lean mass trends alongside total weight. While these consumer devices are not as accurate as DEXA scans, they are consistent enough to detect trends over time. If you see lean mass dropping faster than fat mass, it is a clear signal to increase protein intake and add or intensify resistance training before you lose ground that takes months to rebuild.
Did you know?
In the STEP 1 trial, the DEXA substudy revealed that semaglutide-treated patients lost approximately 39 percent of their weight as lean mass compared to 25 percent in the placebo group. However, when researchers calculated the fat mass index and lean mass index separately, the GLP-1 group still had a net improvement in body composition ratios because the absolute fat loss was so large. This counterintuitive finding means that even with higher lean mass loss, patients on GLP-1 drugs ended up with a healthier body composition than when they started.